Type I Thyroplasty Is Safe in Patients Undergoing Antithrombotic Therapy.

IF 2 4区医学 Q2 OTORHINOLARYNGOLOGY

Orl-Journal for Oto-Rhino-Laryngology Head and Neck Surgery Pub Date : 2023-01-01 DOI:10.1159/000529905

Motohiro Sawatsubashi, Toshiro Umezaki, Yoshikazu Kikuchi, Kazuo Adachi, Takashi Nakagawa

{"title":"Type I Thyroplasty Is Safe in Patients Undergoing Antithrombotic Therapy.","authors":"Motohiro Sawatsubashi, Toshiro Umezaki, Yoshikazu Kikuchi, Kazuo Adachi, Takashi Nakagawa","doi":"10.1159/000529905","DOIUrl":null,"url":null,"abstract":"Introduction: Type I thyroplasty is one of the most useful surgeries for unilateral vocal fold paralysis. The study objective was to determine whether type I thyroplasty is safe and perioperative antithrombotic management is acceptable in patients undergoing antithrombotic therapy.Methods: This is a single-hospital retrospective cohort study. The records of 204 patients who underwent type I thyroplasty at a Japanese university hospital, between 2008 and July 2018 were reviewed. We compared the prothrombin time international normalized ratio, prothrombin time, operative time, intraoperative blood loss, and intra- and postoperative complications between patients who did and did not receive antithrombotic therapy.Results: Of 204 patients, 51 (25%) received antithrombotic therapy (antithrombotic group). The remaining 153 patients were assigned to the control group. There were no significant differences in operative time, intraoperative blood loss, or intraoperative complications between the two groups. Sixteen (31%) patients in the antithrombotic group had a hemorrhage or hematoma in the vocal fold mucosa postoperatively, no patient had airway obstruction necessitating tracheostomy, and all patients recovered with follow-up observation only. There were no cases of intraoperative or postoperative complications, such as ischemic heart disease, ischemic stroke, or deep vein thrombosis.Conclusion: Type I thyroplasty with careful pre- and postoperative management is safe in patients undergoing antithrombotic therapy.","PeriodicalId":49717,"journal":{"name":"Orl-Journal for Oto-Rhino-Laryngology Head and Neck Surgery","volume":"85 3","pages":"163-171"},"PeriodicalIF":2.0000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Orl-Journal for Oto-Rhino-Laryngology Head and Neck Surgery","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000529905","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"OTORHINOLARYNGOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Type I thyroplasty is one of the most useful surgeries for unilateral vocal fold paralysis. The study objective was to determine whether type I thyroplasty is safe and perioperative antithrombotic management is acceptable in patients undergoing antithrombotic therapy.

Methods: This is a single-hospital retrospective cohort study. The records of 204 patients who underwent type I thyroplasty at a Japanese university hospital, between 2008 and July 2018 were reviewed. We compared the prothrombin time international normalized ratio, prothrombin time, operative time, intraoperative blood loss, and intra- and postoperative complications between patients who did and did not receive antithrombotic therapy.

Results: Of 204 patients, 51 (25%) received antithrombotic therapy (antithrombotic group). The remaining 153 patients were assigned to the control group. There were no significant differences in operative time, intraoperative blood loss, or intraoperative complications between the two groups. Sixteen (31%) patients in the antithrombotic group had a hemorrhage or hematoma in the vocal fold mucosa postoperatively, no patient had airway obstruction necessitating tracheostomy, and all patients recovered with follow-up observation only. There were no cases of intraoperative or postoperative complications, such as ischemic heart disease, ischemic stroke, or deep vein thrombosis.

Conclusion: Type I thyroplasty with careful pre- and postoperative management is safe in patients undergoing antithrombotic therapy.

查看原文本刊更多论文

I型甲状腺成形术对接受抗血栓治疗的患者是安全的。

I型甲状腺成形术是单侧声带麻痹最有用的手术之一。该研究的目的是确定I型甲状腺成形术是否安全，以及接受抗血栓治疗的患者围手术期抗血栓管理是否可接受。方法:这是一项单医院回顾性队列研究。回顾了2008年至2018年7月期间在日本一家大学医院接受I型甲状腺成形术的204名患者的记录。我们比较了接受和未接受抗栓治疗的患者的凝血酶原时间国际标准化比率、凝血酶原时间、手术时间、术中出血量以及术中和术后并发症。结果:204例患者中，51例(25%)接受抗栓治疗(抗栓组)。其余153例患者被分配到对照组。两组手术时间、术中出血量、术中并发症无显著差异。抗栓组术后声带黏膜出血或血肿16例(31%)，无气道阻塞需要气管造瘘的病例，均经随访观察痊愈。术中、术后无缺血性心脏病、缺血性脑卒中、深静脉血栓形成等并发症发生。结论:ⅰ型甲状腺成形术在接受抗血栓治疗的患者中，术前和术后管理谨慎是安全的。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Orl-Journal for Oto-Rhino-Laryngology Head and Neck Surgery 医学-耳鼻喉科学

CiteScore

2.80

自引率

7.70%

发文量

审稿时长

6-12 weeks

期刊介绍： ''ORL'' contains concise, original scientific papers of interest for both clinicians and researchers in oto-rhino-laryngology and head and neck surgery. Contributions drawn from the basic sciences cover new knowledge on the anatomy, pathology, pathophysiology, immunology and tumor biology of head and neck and the auditory and vestibular system, the salivary glands, paranasal sinuses and of the organs of the upper respiratory and digestive tract. The practical value of the journal is accentuated by reports of clinical progress in diagnosis and therapy.